Samuel Stupp is Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine, and Biomedical Engineering at Northwestern University. He directs Northwestern’s Simpson Querrey Institute and the Center for Bio-Inspired Energy Science, an Energy Frontiers Research Center funded by the U.S. Department of Energy.

Fraser Stoddart, 2016 Nobel Laureate in Chemistry, was born in Edinburgh, Scotland, in 1942. He obtained all his degrees from Edinburgh University and spent time at Queen’s University, Imperial Chemical Industries and the Universities of Sheffield and Birmingham in the UK before moving to UCLA in the US in 1997. He has mentored 500 undergraduate and graduate students and postdoctoral fellows during his career, has over 1200 publications, and is presently a Board of Trustees Professor of Chemistry at Northwestern University.

Heather Wolff joined Decibel in February 2018 as the head of clinical development operations for Decibel Therapeutics. Heather is responsible for Decibel’s clinical operations, regulatory operations, medical writing and data management functions, providing leadership around the company’s development programs. She has a long track record in clinical development, with a focus on building and leading data management groups.

Moxham has over 20 years of drug discovery experience, primarily at Eli Lilly and Company where he most recently served as vice president, quantitative biology. In this role, he helped grow Lilly’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art lab facility focused on preclinical and translational research. Previously, he was associate vice president, oncology research at Lilly where he established and led the company’s biomarker group.

John Keilty joined Decibel from Third Rock Ventures, where he served as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals, where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics.